Founded in Pittsburgh, Pennsylvania, D.Sole is dedicated to revolutionizing the early diagnosis and prognostic evaluation of Diabetic Peripheral Neuropathy (DPN). The company's core mission is to provide a non-invasive, at-home solution that helps patients manage and monitor foot complications caused by diabetes. Their primary product is an insole equipped with sensors that track the loss of sensation in the feet, paired with a custom mobile application for real-time monitoring and alerts. D.Sole targets diabetic patients who are at risk of developing severe foot conditions, aiming to prevent ulcers and gangrene through early detection.

D.Sole has garnered attention from notable healthcare professionals and investors who recognize the potential impact of their innovative approach to diabetic care. The company has achieved significant milestones, including successful clinical trials and partnerships with major medical institutions. Their technology has been praised for its potential to reduce healthcare costs associated with diabetic foot complications, offering a proactive solution that enhances patient quality of life. Overall, D.Sole is making a substantial impact in the field of diabetes management through its cutting-edge, AI-based monitoring system.